CD44 and hepatocellular carcinoma: In hepatocellular carcinoma (HCC), tumor-associated macrophages promote CD44+ stem-like cell expansion, and IL-6/STAT3 signaling inhibition using Tocilizumab (TCZ) inhibits this expansion [5].